Dyadic International (DYAI) Operating Expenses (2018 - 2026)
Dyadic International's (DYAI) quarterly Operating Expenses came in at $3.0 million in Q1 2026, up 25.78% year-over-year from $2.4 million in Q1 2025, and up 43.41% quarter-over-quarter from $2.1 million in Q4 2025.
Analysis
Dyadic International (DYAI) Operating Expenses (2018 - 2026) Analysis & Trends
Dyadic International has disclosed Operating Expenses across 9 years of filings, most recently posting $3.0 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 25.78% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $10.9 million (up 16.81% YoY), while the FY2025 annual figure was $10.3 million, up 9.44% from the prior year.
- Operating Expenses came in at $3.0 million for Q1 2026 at Dyadic International, up from $2.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $4.0 million in Q2 2022 to a low of $2.1 million in Q4 2025.
- Average Operating Expenses over 5 years is $2.8 million, with a median of $2.7 million recorded in 2022.
- Year-over-year, Operating Expenses tumbled 99.91% in 2022 and surged 43.05% in 2025.
- Over 5 years, Operating Expenses stood at $3.0 million in 2022, then dropped by 4.29% to $2.9 million in 2023, then slipped by 17.78% to $2.3 million in 2024, then decreased by 10.48% to $2.1 million in 2025, then soared by 43.41% to $3.0 million in 2026.
- Per Business Quant data, the three most recent Operating Expenses figures were $3.0 million in Q1 2026, $2.1 million in Q4 2025, and $3.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.84 Bn | 192.85 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 180.29 Bn | 177.11 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 131.27 Bn | 123.42 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 81.95 Bn | 73.96 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 60.32 Bn | 55.13 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 53.94 Bn | 48.80 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.35 Bn | 30.04 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.85 Bn | 30.56 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 29.08 Bn | 29.08 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Dyadic International | 18.44 Mn | 10.48 Mn | - | 3.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 3.01 Mn |
| Dec 31, 2025 | 2.10 Mn |
| Sep 30, 2025 | 3.09 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.40 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 2.16 Mn |
| Jun 30, 2024 | 2.43 Mn |
| Mar 31, 2024 | 2.46 Mn |
| Dec 31, 2023 | 2.86 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 3.03 Mn |
| Dec 31, 2022 | 2.98 Mn |
| Sep 30, 2022 | 2.74 Mn |
| Jun 30, 2022 | 3.98 Mn |
| Mar 31, 2022 | 3.39 Mn |
| Dec 31, 2021 | 4.53 Mn |
| Sep 30, 2021 | 4.02 Mn |
| Jun 30, 2021 | 4.80 Mn |